The prognostic and predictive value of serum CA19.9 in pancreatic cancer
Jeremy L. Humphris(Garvan Institute of Medical Research), David K. Chang(Garvan Institute of Medical Research), Amber L. Johns(Garvan Institute of Medical Research), Christopher J. Scarlett(Garvan Institute of Medical Research), Marina Pajic(Garvan Institute of Medical Research), Marc D. Jones(Garvan Institute of Medical Research), Emily K. Colvin(Garvan Institute of Medical Research), Adnan Nagrial(Garvan Institute of Medical Research), Venessa Chin(Garvan Institute of Medical Research), Lorraine A. Chantrill(Garvan Institute of Medical Research), Jaswinder S. Samra, Anthony J. Gill(The University of Sydney), James G. Kench(The University of Sydney), Neil D. Merrett(Bankstown Lidcombe Hospital), Anibh M. Das(Bankstown Lidcombe Hospital), Elizabeth A. Musgrove(Garvan Institute of Medical Research), R. L. Sutherland(Garvan Institute of Medical Research), Andrew V. Biankin(Garvan Institute of Medical Research)
Cited by 300Open Access
Abstract
Related Papers
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
John P. Neoptolemos, Deborah Stocken, Helmut Friess et al.|New England Journal of Medicine|2004|2.7k